Trial watch: Oncolytic viruses for cancer therapy.

Introduction

Oncolytic viruses

Using viruses against cancer is not a particularly new concept, as it was initially put forward at the beginning of the 20th century. 1 Still, it was not until the 1950s that the antineoplastic potential of (naturally occurring) viruses begun to be tested in preclinical settings as well as in patients, most often with deceiving results in terms of either safety or efficacy. 2 - 5 Throughout the following three decades, the clinical interest in viruses as antineoplastic agents declined, even though a few studies reported encouraging safety data and even anecdotic cases of tumor regression. 5 - 7 The possibility of using viruses as highly specific tumor-targeting tools came back under the limelight only in the late 1990s, along with the establishment of modern genetic engineering technologies. 8 - 10 Since then, the clinical interest in oncolytic (and oncotropic) viruses has never declined again.

The term “oncolytic viruses” is generally employed to indicate non-pathogenic viral particles that specifically infect cancer cells, and hence cause their demise, while leaving unaffected non-malignant tissues. 11 From a strict conceptual standpoint, oncolytic viruses differ from their oncotropic counterparts in that while the latter only exhibit a specific tropism for malignant cells, the former (be they replication-competent or not) kill their hosts upon infection (via several mechanisms, see below). 9 Thus, oncotropic viruses (e.g., baculovirus, canarypox virus and canine parvovirus) efficiently enter malignant cells (and hence can be used as vectors for anticancer gene therapy) but are unable to complete the viral cycle and hence fail to exert major cytotoxic effects. 12 - 14 Conversely, bona fide oncolytic viruses selectively infect cancer cells and kill them, either as a mere consequence of viral replication (cytopathic effect, mediated by replication-competent viruses only) or following the expression of endogenous or exogenous cytotoxic gene products (suicide gene therapy, mediated by both replication-competent and replication-incompetent virions). 9 , 11 A detailed description of all the viral species that have been tested for their oncolytic potential or genetically engineered in this sense—each of which is associated with specific advantages and drawbacks—exceed the scope of the present Trial Watch and can be found in refs. 9 and 11 .

Tropism and selectivity of oncolytic viruses

The specific targeting of malignant cells is an absolute requirement for the clinical success of oncolytic virotherapy. In line with this notion, during the past two decades several distinct strategies have been pursued to improve the oncotropism of naturally occurring viruses (some of which exhibit an inherent preference for malignant cells), as well as to increase their oncoselective cytotoxic potential. 9 , 11 The strategies that have been investigated to ameliorate the selectivity of oncolytic viruses include (1) the genetic manipulation of viral envelopes or capsids to provide viruses with a strict specificity for cells bearing a tumor-associated surface marker ( transductional targeting ); 15 , 16 (2) the expression of one or more genes that are essential for the viral cycle under the control of promoters that functions only in transformed cells, including tissue-specific and hypoxia-responsive promoters ( transcriptional targeting ); 17 - 20 (3) the insertion of essential viral genes downstream of internal ribosome entry sites (IRESs) that cannot be used as translational origins in specific tissues ( translational targeting ); 21 (4) the use of so-called “destabilization domains,” rendering essential viral products inherently unstable unless a stabilizing chemical is administered (in a tissue-restricted manner) ( post-translational targeting ); 22 , 23 (5) the deletion of one or a few virulence factors, resulting in attenuated viral strains that are able to replicate only in cells bearing cancer-associated alterations in specific signal transduction pathways, such as the hyperactivation of RAS or the inactivation of p53 ( oncogenetic targeting ); 24 - 28 and (6) the insertion of tissue-specific microRNA-binding elements in the 3′-UTR of essential viral genes, allowing tissues that express such microRNAs to escape productive infection ( microRNA targeting ). 29 - 32

Alongside, great efforts have been dedicated at rendering oncolytic viruses increasingly more toxic for cancer cells, well beyond the cytopathic effect normally mediated by replication-competent particles. Strategies that have been undertaken in this sense include the integration into the viral genome of sequences coding for: (1) enzymes that can transform a non-toxic pro-drug into a lethal cytotoxic chemical, such as the thymidine kinase (TK) of herpes simplex viruses (HSVs), converting ganciclovir into deoxyguanosine triphosphate; 33 , 34 or cytosine deaminase, catalyzing the conversion of 5-fluorocytosine into 5-fluorouracil; 35 - 37 (2) proteins that (at least potentially) exert tumor-restricted cytotoxic functions, such as wild-type p53 or death receptor ligands (e.g., FASL); 38 , 39 and (3) short-hairpin RNAs targeting proteins that are specifically required for the survival of malignant cells, such as survivin. 40 A detailed description of these approaches can be found in refs. 11 and 41 . Of note, some viral particles are capable of inducing the demise of malignant (but not normal) cells upon uncoating even in the absence of viral gene expression. 42 The precise molecular mechanisms underlying this phenomenon remain obscure, yet its efficacy appears to be linked to the number of virions actually entering target cells and being uncoated. Along similar lines, a long list of viral proteins exerts bona fide tumor-selective pro-apoptotic functions. 43 For example, both apoptin, a 15 kDa protein encoded by the chicken anemia virus, and the polypeptide coded by the adenoviral E4 open reading frame have been shown to preferentially trigger the apoptotic demise of malignant, as opposed to non-transformed, cells. 44 - 46

Immunogenic activity of oncolytic viruses

Contrarily to long-standing beliefs, the antineoplastic potential of oncolytic virotherapy is not a mere consequence of the cytopathic effect, but rather involves (at least in a majority of settings) the induction of a tumor-specific immune response. 9 , 11 , 47 , 48 In line with this notion, oncolytic viruses genetically engineered to drive the production of various immunostimulatory factors have been shown to mediate more robust therapeutic effects than their non-engineered counterparts. Proof-of-principle evidence in support of this concept has been generated for oncolytic viruses that express membrane-bound co-stimulatory molecules, such as CD40 ligand (CD40L) and CD80, 49 - 52 as well as multiple distinct immunostimulatory cytokines encompassing interleukin (IL)-2, 53 IL-12, 54 - 56 IL-15 57 - 59 and granulocyte macrophage colony-stimulating factor (GM-CSF). 55 , 60 - 62 In addition, the clinical efficacy of oncolytic virotherapy appears to be robustly ameliorated by some degree of initial immunosuppression (facilitating viral replication and spread) followed by the provision of immunostimulatory factor (boosting antitumor immunity). 9 , 11

Obstacles against efficient oncolytic virotherapy

The administration of oncolytic viruses as a standalone therapeutic intervention has been shown to rarely induce the complete, long-term regression of established tumors in vivo, owing to several reasons. 9 , 11 First, preclinical and clinical evidence indicates that oncolytic viruses often infect neoplastic lesions in a rather heterogeneous and incomplete fashion, irrespective of administration route and whether viruses are replication-competent or not. 63 - 67 A prominent role in this context is played by tumor size 68 as well as physicochemical barriers to infection, including the layers of connective tissue, 69 , 70 the elevated interstitial pressure, 71 the poorly permissive vasculature 72 and the large areas of necrosis/calcification 73 , 74 that generally characterize solid tumors. Second, oncolytic viruses often establish a “dynamic equilibrium” with tumors, that is, a state in which viral infection affects a spatially-restricted population of malignant cells, rather than the entire lesion, and is continuously counterbalanced by the proliferation of non-infected cancer cells. 75 , 76 Of note, while in immunodeficient settings such an equilibrium may be relatively stable (and hence de facto impede tumor growth), 77 at some stage the immune system is expected to eradicate the viral infection in immunocompetent animals, thereby tilting the tip of the balance in favor of malignant cells. Third, similar to what commonly observed in the course of chemo- and radiotherapy, malignant cells are prone to become resistant to oncolytic virotherapy over time, 67 , 72 , 77 - 79 presumably linked to their intrinsic genomic instability and propensity to accumulate mutations. 80 , 81 Interestingly, cancer cells that had been rendered resistant to the parvovirus H1 in vitro were found to be cross-protected against the cytotoxic effects of tumor necrosis factor α (TNFα), 82 - 84 an observation with profound implications for the development of combination chemoimmunotherapeutic regimens involving oncolytic viruses. Fourth, a large fraction of the population has previously been exposed to the naturally occurring viruses that are commonly employed to generate therapeutic strains , de facto being fully protected against their infectious potential by high levels of neutralizing antibodies. 85 , 86 Along similar lines, some viral particles, including HSV1- and murine leukemia virus-derived viruses, are particularly prone to inactivation by the complement system. 87 , 88 Fifth, unless specific preventive measures are undertaken, oncolytic viruses administered i.v. are massively sequestered (most often upon opsonization) by the mononuclear phagocytic system (MPS) of the liver and spleen. 89 , 90 On one hand, this significantly restricts the amount of infectious particles that are capable of reaching the tumor site, de facto compromising transduction efficiency and hence therapeutic effects. 91 On the other hand, the accumulation of viral particles into the liver and the spleen may trigger the release of pro-inflammatory cytokines, potentially driving serious, dose-limiting toxicities. 92 , 93 Sixth, although great progresses have already been made in this sense, the use of viruses remains intrinsically associated with some threats, in particular when cancer patients—who often exhibit some degree of immunosuppression—are concerned. 94 - 96 In this respect, one problematic issue relates to the fact that all viruses are potentially immunogenic and hence can cause—at the therapeutic doses of 10 12 particles—unwarranted side effects including transient hepatic inflammation (see above) and low-grade disseminated intravascular coagulation. 97 , 98 In addition, great concerns have been raised by the case of three children who developed a leukemic syndrome following the reinfusion of retrovirally transduced T cells for the treatment of a severe monogenic immunodeficiency, most likely owing to the integration of the viral vector in the proximity of the LMO2 oncogene. 99 , 100

Taken together, these observations highlight an urgent need for the development of ever more refined oncolytic viruses and the design of combinatorial strategies by which the obstacles described above would be—at least in part—circumvented. Several approaches have already been conceived to ameliorate the therapeutic potential of oncolytic virotherapy, including (among several others) (1) the use of coating polymers to shield viral particles from the neutralizing effects of circulating antibodies and the complement system as well as from sequestration by the MPS; 101 - 103 (2) the pre-administration of molecules that selectively increase the permeability of tumor vessels (e.g., IL-2, TNFα, histamine, bradykinin analogs) or aggressive chemotherapy, to reduce interstitial pressure; 104 , 105 (3) the intratumoral administration of antifibrotic agents, such as the FDA-approved antihypertensive drug losartan, or enzymes that degrade components of the extracellular matrix, such as hyaluronidase; 106 , 107 (4) the development of oncolytic viruses that—in addition to cytotoxic factors—express extracellular matrix-degrading enzymes like hyaluronidase; 108 and (5) the careful modulation of the immune system (for instance with cyclophosphamide, which at high doses exerts potent immunosuppressive effects) 109 - 111 to avoid premature antiviral responses that would compromise viral spread (and hence therapeutic efficacy). 112

The safety and preliminary antineoplastic effects of several naturally occurring and genetically modified viruses have been/are being tested in multiple distinct clinical trials (see below). As it stands, however, no oncolytic viruses are licensed by the U.S. FDA for use in cancer patients (source www.fda.gov ). Conversely, gendicine, an oncotropic, recombinant adenovirus engineered to express wild-type p53, has been approved for the treatment of subjects affected by head and neck squamous cell carcinoma in China as early as in 2003. 113 , 114 Along the lines of our monthly Trial Watch series, 115 - 128 here we will briefly review the progress of recent clinical trials that have investigated/are investigating the antineoplastic potential of oncolytic viruses.

Clinical Development of Oncolytic Viruses

Literature

As mentioned above, the possibility of using viruses to specifically kill neoplastic cells begun to attract the attention of clinicians, and hence to be tested in patients, in the 1950s. 1 In this context, hundreds of patients bearing a wide array of distinct neoplasms received highly impure viral preparations (including infected body fluids and so-called “oncolysates,” i.e., autologous malignant cells or established cancer cell lines killed by viruses ex vivo), via almost every conceivable route of administration. 3 , 11 , 129 , 130 Most often, these attempts failed to drive any therapeutic response as viruses were rapidly inactivated by the immune system. Nevertheless, sporadic cases of tumor regression were reported, in particular among immunodeficient patients, who however were at increased risk of death owing to the spread of the viral infection to healthy tissues. 3 , 11 , 129 , 130 Perhaps the most impressive results of this period were obtained by Asada and colleagues, who reported 37 tumor regressions among 90 terminal cancer patients treated with a non-attenuated strain of the mumps virus. 131

In 1991, Martuza et al. were the first to demonstrate that a genetically manipulated variant of HSV lacking the TK-coding gene (and hence displaying attenuated virulence) could be successfully employed to treat glioblastoma in mice. 132 This report de facto paved the way to modern virotherapy and drove an intense wave of preclinical and clinical investigation that has not yet come to an end. Since then indeed, dozens—if not hundreds—of distinct oncolytic and oncotropic viruses have been developed and tested in preclinical models. An exhaustive discussion of the preclinical results obtained during the last two decades with oncolytic viruses can be found in refs. 9 , 11 , 133 and 134 . Alongside, several oncolytic viruses entered the clinics and their safety and preliminary antineoplastic potential begun to be investigated in patients affected by a wide variety of (mostly solid) tumors. 11 , 135 , 136

Adenoviruses and HSVs represent by far the oncolytic viruses most extensively investigated (at both the preclinical and clinical level) and developed so far. 137 - 139 Indeed, attenuated adenoviral strains, most often lacking the genes coding for E3 or the anti-apoptotic protein E1B55K, 43 have already been used in patients affected by glioma, 140 sarcoma, 141 head and neck cancer (HNC), 97 , 142 - 145 pancreatic cancer, 146 , 147 colorectal carcinoma (CRC), 147 - 149 prostate carcinoma, 150 - 152 ovarian cancer, 153 , 154 bladder carcinoma 61 and multiple solid tumors. 155 , 156 Along similar lines, the safety and therapeutic potential of attenuated HSVs, near to invariably lacking the gene coding for the main neurovirulence factor γ34.5, 157 have been tested in subjects with glioma, 158 - 162 breast carcinoma, 163 HNC, 164 - 166 melanoma, 167 - 170 pancreatic carcinoma, 171 CRC hepatic metastases 172 and various solid malignancies. 173 Most of the remaining clinical trials that have been completed so far were designed to evaluated the safety and the oncolytic profile of stains of Newcastle disease virus (in subjects affected by glioma and other solid tumors), 174 - 176 parvovirus (in glioblastoma multiforme patients), 177 reovirus (in individuals bearing glioma, melanoma and other solid tumors) 178 - 181 and vaccinia virus (in hepatocellular carcinoma and melanoma patients). 62 , 182 - 184 The majority of these studies were Phase I/II trials, most often reporting reassuring safety data and sporadic antineoplastic activity, even when oncolytic viruses were employed as standalone therapeutic interventions. In this setting, the most encouraging results have surely been recorded with talimogene laherparepvec (developed by Amgen, also known as OncoVex), an oncolytic γ34.5-deficient variant of HSV genetically manipulated to drive the expression of GM-CSF by infected cells. 185 As a single agent administered i.t., talimogene laherparepvec induced the complete regression of both injected and distant lesions in 8 out of 50 metastatic melanoma patients. 170 A similar efficacy has been observed with JX954, an oncolytic vaccinia virus engineered to express GM-CSF that was shown to induce objective responses in a consistent percentage of hepatocellular carcinoma patients. 62 , 184 In addition, multiple studies have shown that combining oncolytic viruses with conventional radio- or chemotherapeutic is generally safe and improves (to some extent) the rates of clinical responses. 141 , 143 , 145 , 146 , 149 - 152 , 166 , 174 , 179 In summary, accumulating clinical data strongly support the development of oncolytic virotherapy.

Recent, ongoing clinical trials

Nowadays (April 2013), official sources list no less than 52 recent (started after January 1, 2008), ongoing (not withdrawn, terminated or completed at the day of submission), clinical trials assessing the safety and antineoplastic potential of oncolytic viruses in cancer patients ( Table 1 ). One third (17) of these studies are investigating the activity of a wild-type reovirus (serotype 3 Dearing, developed by Oncolytics Biotech under the name of Reolysin ® ) 186 administered i.v. or (rarely) i.p., often in combination with conventional therapeutic regimens, to patients affected by multiple myeloma ( NCT01533194 ), HNC ( NCT00753038 ; NCT01166542 ), breast carcinoma ( NCT01656538 ), melanoma ( NCT00651157 ; NCT00984464 ), lung cancer ( NCT00861627 ; NCT00998192 ; NCT01708993 ), pancreatic carcinoma ( NCT00998322 ; NCT01280058 ), CRC ( NCT01274624 ; NCT01622543 ), prostate cancer ( NCT01619813 ), reproductive tract neoplasms ( NCT00602277 ; NCT01199263 ) or pediatric solid tumors ( NCT01240538 ). Eight clinical trials are assessing the safety and antineoplastic profile of JX594 (developed by Transgene as Pexa-Vec), administered i.v. most often as a standalone therapeutic intervention, in subjects bearing hepatocellular carcinoma ( NCT01171651 ; NCT01387555 ; NCT01636284 ), CRC ( NCT01380600 , NCT01394939 ; NCT01469611 ) or chemorefractory solid tumors ( NCT00625456 ; NCT01169584 ). The highly attenuated oncolytic vaccinia virus GL-ONC1 (developed by Genelux, also known as GLV-1h68) 187 is being tested in combination with chemoradiotherapy for the treatment of HNC patients ( NCT01584284 ), as a standalone therapeutic intervention administered intrapleurally in lung cancer patients ( NCT01766739 ), and upon intravenous or intraperitoneal delivery in subjects affected by advanced solid tumors or peritoneal carcinomatosis, respectively ( NCT00794131 ; NCT01443260 ).

In addition, clinical trials are currently ongoing for investigating the safety and antineoplastic activity of: (1) talimogene laherparepvec, 62 administered i.t.—as a standalone intervention or combined with systemic ipilimumab 188 , 189 —to melanoma patients ( NCT00769704 ; NCT01368276 ; NCT01740297 ); (2) naturally occurring coxsackievirus A21 (developed by Viralytics as Cavatak™), 190 administered i.t. as a single agent to melanoma patients ( NCT01227551 ; NCT01636882 ); (3) CGTG-102 (an oncolytic adenovirus engineered to drive the local expression of GM-GSF, developed by Oncos), 191 administered i.t. or i.v.—alone or in combination with metronomic cyclophosphamide—to patients affected by advanced solid tumors ( NCT01437280 ; NCT01598129 ); (4) DNX-2401 (a genetically manipulated replication-competent adenovirus developed by DNAtrix), 192 , 193 given i.t. as a standalone agent to glioblastoma and glioma patients ( NCT00805376 ; NCT01582516 ); (5) HSV1716 (a γ34.5-deficient variant of HSV developed by Virttu as Seprehvir ® ), 169 administered intrapleurally or intratumorally to individuals affected by mesothelioma or solid tumors ( NCT01721018 ; NCT00931931 ); (6) Toca511 ® (a retrovirus engineered to express cytosine deaminase, developed by Tocagen), given alone or in combination with 5-fluorocytosine to subjects affected by astrocytoma, glioblastoma, oligoastrocytoma and oligodendrocytoma ( NCT01156584 ; NCT01470794 ); (7) the Seneca Valley virus (a replication-competent oncolytic picornavirus also known as NTX-010), 194 administered i.v. as a single agent or combined with metronomic cyclophosphamide to patients with lung cancer or neuroendocrine tumors, respectively ( NCT01017601 ; NCT01048892 ); (8) PVSRIPO (an nonpathogenic recombinant poliovirus), 195 given i.t. as a standalone intervention to glioblastoma patients ( NCT01491893 ); (9) the attenuated measles virus commonly used as a prophylactic vaccine, 75 , 196 given intrapleurally as a single therapeutic agent to mesothelioma patients ( NCT01503177 ); (10) CG0070 (a conditionally replicating GM-CSF-armed oncolytic adenovirus), 61 , 197 instilled intravesically as a single agent to subjects with bladder carcinoma ( NCT01438112 ); (11) HF10 (a spontaneous attenuated variant of HSV1), 198 , 199 administered i.t. as a standalone intervention to individuals affected by refractory HNC or other solid tumors ( NCT01017185 ); (12) an attenuated lentogenic isolate of the Newcastle disease virus (known as NDV-HUJ), 174 , 200 given i.v. as a single agent to glioblastoma, neuroblastoma and sarcoma patients ( NCT01174537 ); (13) parvovirus H1 (a naturally occurring parvoviral variant developed by Oryx Verwaltungs as ParvOryx ® ), 177 , 201 administered i.v. or i.t. as a standalone therapeutic intervention to glioblastoma patients ( NCT01301430 ); and (14) a variant of the vesicular stomatitis virus engineered to drive the expression of interferon β (IFNβ), 202 , 203 given i.t. as a single agent to subjects affected by hepatocellular carcinoma ( NCT01628640 ). The large majority of these studies are Phase I/II clinical trials, with the notable exceptions of NCT01438112 (assessing the antineoplastic activity of CG0070 in bladder carcinoma patients), NCT01166542 (evaluating the efficacy of Reolysin ® in HNC patients) as well as NCT00769704 and NCT01368276 (both investigating the antineoplastic potential of talimogene laherparepvec in melanoma patients). Of note, Amgen representatives have very recently declared that NCT00769704 met its primary endpoint of durable response rate, defined as the rate of complete or partial response lasting continuously for at least six months (source www.amgen.com/media/media_pr_detail.jsp?releaseID=1798143 ). Thus, talimogene laherparepvec appears relatively close to being approved by FDA for use in melanoma patients.

Concluding Remarks

During the last two decades, great efforts have been dedicated at the development of viruses that would selectively and efficiently kill malignant cells while sparing their normal counterparts. Accumulating clinical evidence indicates that oncolytic virotherapy is generally well tolerated and, at least under specific circumstances, exerts durable antineoplastic effects. Importantly, although some degree of immunosuppression initially favors transduction and viral spread, the antineoplastic potential of oncolytic viruses in fine appears to rely on the elicitation of tumor-specific immune responses. 9 , 11 , 47 , 48 This notion is best exemplified by the fact that oncolytic viruses engineered to drive the expression of immunostimulatory factors, such as GM-CSF and IFNβ, are usually more efficient at promoting tumor regression than their naturally occurring counterparts. 52 , 173 , 202 , 203

As oncolytic virotherapy may soon move from the bench to the beside, future studies will have to elucidate to which extent, if any, the clinical efficacy of oncolytic viruses can be improved by combining them with appropriate immunomodulatory interventions. At least theoretically, both (pre-conditioning) immunosuppressive regimens and robust immunostimulatory interventions such as the local or systemic administration of recombinant cytokines, 118 , 204 Toll-like receptor (TLR) agonists, 119 , 120 , 205 , 206 or immune checkpoint-blocking antibodies, 115 , 124 , 188 , 207 may significantly boost the therapeutic effects of oncolytic virotherapy, yet optimal schedules and administration routes to achieve this objective will have to be carefully defined. Rommelfanger and colleagues have indeed demonstrated that the intratumoral administration of lipopolysaccharide (a natural TLR2/TLR4 agonist) significantly enhances the antineoplastic potential of an oncolytic vesicular stomatitis virus administered i.t. to melanoma-bearing mice, yet drives a lethal inflammatory syndrome in the majority of animals when viral particles are given i.v. 208 As several distinct oncolytic viruses delivered i.t. have been shown to induce clinical responses even in distant, non-injected lesions, 62 , 168 , 170 the local—as opposed to systemic—route of administration stands out as a safe and efficient alternative in this setting. Of note, encouraging results have also been obtained by combining oncolytic viruses with selected chemotherapeutics, such as the microtubular inhibitor paclitaxel. 209 It is tempting to speculate, yet remains to be formally demonstrated, that such an effect may originate from the capacity of some combinatorial antineoplastic regimens to elicit immunogenic cell death. 210 , 211 Irrespective of this unresolved issue, the rational combination of oncolytic virotherapy with immunotherapy and chemotherapy is expected to drive the development of ever more efficient clinical protocols for the treatment of cancer.

† These authors share senior co-authorship.

Previously published online: www.landesbioscience.com/journals/oncoimmunology/article/24612

Acknowledgments

Authors are supported by the Ligue Nationale contre le Cancer (équipe labellisée), Agence Nationale de la Recherche, AXA Chair for Longevity Research, Association pour la Recherche sur le Cancer, Cancéropôle Ile-de-France, Institut National du Cancer (INCa), Fondation Bettencourt-Schueller, Fondation de France, Fondation pour la Recherche Médicale, the European Commission (ArtForce), the European Research Council, the LabEx Immuno-Oncology, the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (Socrate), the Cancer Research and Personalized Medicine (Carpem) consortium, and the Paris Alliance of Cancer Research Institutes (Pacri).

Abbreviations:

CD40 ligand

colorectal carcinoma

granulocyte monocyte colony-stimulating factor

head and neck cancer

herpes simplex virus

interferon

interleukin

internal ribosome entry site

mononuclear phagocytic system

thymidine kinase

Toll-like receptor

tumor necrosis factor α

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1 Kelly E Russell SJ History of oncolytic viruses: genesis to genetic engineering Mol Ther 2007 15 651 9 17299401 10.1038/sj.mt.6300108

2 Pack GT Note on the experimental use of rabies vaccine for melanomatosis AMA Arch Derm Syphilol 1950 62 694 5 10.1001/archderm.1950.01530180083015 14770525

3 Southam CM Present status of oncolytic virus studies Trans N Y Acad Sci 1960 22 657 73 10.1111/j.2164-0947.1960.tb00739.x 13833074

4 Southam CM Hilleman MR Werner JH Pathogenicity and oncolytic capacity of RI virus strain RI-67 in man J Lab Clin Med 1956 47 573 82 13307092

5 Huebner RJ Rowe WP Schatten WE Smith RR Thomas LB Studies on the use of viruses in the treatment of carcinoma of the cervix Cancer 1956 9 1211 8 10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7 13383455

6 Newman W Southam CM Virus treatment in advanced cancer; a pathological study of fifty-seven cases Cancer 1954 7 106 18 10.1002/1097-0142(195401)7:1<106::AID-CNCR2820070112>3.0.CO;2-L 13126905

7 Wheelock EF Dingle JH Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report N Engl J Med 1964 271 645 51 10.1056/NEJM196409242711302 14170843

8 Stanford MM Bell JC Vähä-Koskela MJ Novel oncolytic viruses: riding high on the next wave? Cytokine Growth Factor Rev 2010 21 177 83 10.1016/j.cytogfr.2010.02.012 20219409

9 Vähä-Koskela MJ Heikkilä JE Hinkkanen AE Oncolytic viruses in cancer therapy Cancer Lett 2007 254 178 216 10.1016/j.canlet.2007.02.002 17383089 PMC7126325

10 Quetglas JI John LB Kershaw MH Alvarez-Vallina L Melero I Darcy PK Virotherapy, gene transfer and immunostimulatory monoclonal antibodies Oncoimmunology 2012 1 1344 54 10.4161/onci.21679 23243597 PMC3518506

11 Russell SJ Peng KW Bell JC Oncolytic virotherapy Nat Biotechnol 2012 30 658 70 10.1038/nbt.2287 22781695 PMC3888062

12 Griffith TS Kawakita M Tian J Ritchey J Tartaglia J Sehgal I Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses J Natl Cancer Inst 2001 93 998 1007 10.1093/jnci/93.13.998 11438565

13 Mäkelä AR Matilainen H White DJ Ruoslahti E Oker-Blom C Enhanced baculovirus-mediated transduction of human cancer cells by tumor-homing peptides J Virol 2006 80 6603 11 10.1128/JVI.00528-06 16775347 PMC1488948

14 Singh P Destito G Schneemann A Manchester M Canine parvovirus-like particles, a novel nanomaterial for tumor targeting J Nanobiotechnology 2006 4 2 10.1186/1477-3155-4-2 16476163 PMC1386698

15 Ayala-Breton C Barber GN Russell SJ Peng KW Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins Hum Gene Ther 2012 23 484 91 10.1089/hum.2011.146 22171635 PMC3360499

16 Muik A Kneiske I Werbizki M Wilflingseder D Giroglou T Ebert O Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism J Virol 2011 85 5679 84 10.1128/JVI.02511-10 21450833 PMC3094995

17 Passer BJ Cheema T Zhou B Wakimoto H Zaupa C Razmjoo M Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication Cancer Res 2010 70 3890 5 10.1158/0008-5472.CAN-10-0155 20424118 PMC3763489

18 Lee CY Bu LX DeBenedetti A Williams BJ Rennie PS Jia WW Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors Mol Ther 2010 18 929 35 10.1038/mt.2010.26 20179676 PMC2890095

19 Cuevas Y Hernández-Alcoceba R Aragones J Naranjo-Suárez S Castellanos MC Esteban MA Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas Cancer Res 2003 63 6877 84 14583486

20 Post DE Van Meir EG A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy Oncogene 2003 22 2065 72 10.1038/sj.onc.1206464 12687009

21 Yang X Chen E Jiang H Muszynski K Harris RD Giardina SL Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay J Virol Methods 2009 155 44 54 10.1016/j.jviromet.2008.09.020 18951922 PMC2650828

22 Banaszynski LA Sellmyer MA Contag CH Wandless TJ Thorne SH Chemical control of protein stability and function in living mice Nat Med 2008 14 1123 7 10.1038/nm.1754 18836461 PMC2605277

23 Glass M Busche A Wagner K Messerle M Borst EM Conditional and reversible disruption of essential herpesvirus proteins Nat Methods 2009 6 577 9 10.1038/nmeth.1346 19578384

24 Stojdl DF Lichty BD tenOever BR Paterson JM Power AT Knowles S VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents Cancer Cell 2003 4 263 75 10.1016/S1535-6108(03)00241-1 14585354

25 Sarinella F Calistri A Sette P Palù G Parolin C Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway Gene Ther 2006 13 1080 7 10.1038/sj.gt.3302770 16554839

26 Krishnamurthy S Takimoto T Scroggs RA Portner A Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines J Virol 2006 80 5145 55 10.1128/JVI.02618-05 16698995 PMC1472132

27 Stojdl DF Lichty B Knowles S Marius R Atkins H Sonenberg N Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus Nat Med 2000 6 821 5 10.1038/77558 10888934

28 Coffey MC Strong JE Forsyth PA Lee PW Reovirus therapy of tumors with activated Ras pathway Science 1998 282 1332 4 10.1126/science.282.5392.1332 9812900

29 Sugio K Sakurai F Katayama K Tashiro K Matsui H Kawabata K Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences Clin Cancer Res 2011 17 2807 18 10.1158/1078-0432.CCR-10-2008 21346145

30 Kelly EJ Nace R Barber GN Russell SJ Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting J Virol 2010 84 1550 62 10.1128/JVI.01788-09 19906911 PMC2812322

31 Edge RE Falls TJ Brown CW Lichty BD Atkins H Bell JC A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication Mol Ther 2008 16 1437 43 10.1038/mt.2008.130 18560417

32 Kelly EJ Hadac EM Greiner S Russell SJ Engineering microRNA responsiveness to decrease virus pathogenicity Nat Med 2008 14 1278 83 10.1038/nm.1776 18953352

33 Wildner O Blaese RM Morris JC Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase Cancer Res 1999 59 410 3 9927055

34 Tseng JC Zanzonico PB Levin B Finn R Larson SM Meruelo D Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET J Nucl Med 2006 47 1136 43 16818948

35 Foloppe J Kintz J Futin N Findeli A Cordier P Schlesinger Y Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus Gene Ther 2008 15 1361 71 10.1038/gt.2008.82 18480846

36 Liu Y Deisseroth A Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy Cancer Gene Ther 2006 13 845 55 10.1038/sj.cgt.7700962 16710344

37 Leveille S Samuel S Goulet ML Hiscott J Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy Cancer Gene Ther 2011 18 435 43 10.1038/cgt.2011.14 21394109

38 Shinoura N Yoshida Y Asai A Kirino T Hamada H Adenovirus-mediated transfer of p53 and Fas ligand drastically enhances apoptosis in gliomas Cancer Gene Ther 2000 7 732 8 10.1038/sj.cgt.7700160 10830720

39 Zhao L Dong A Gu J Liu Z Zhang Y Zhang W The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer Cancer Gene Ther 2006 13 1011 22 10.1038/sj.cgt.7700969 16799468

40 Jiang G Li J Zeng Z Xian L Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma Cancer Biol Ther 2006 5 435 40 10.4161/cbt.5.4.2542 16575205

41 Cattaneo R Miest T Shashkova EV Barry MA Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded Nat Rev Microbiol 2008 6 529 40 10.1038/nrmicro1927 18552863 PMC3947522

42 Labrada L Bodelón G Viñuela J Benavente J Avian reoviruses cause apoptosis in cultured cells: viral uncoating, but not viral gene expression, is required for apoptosis induction J Virol 2002 76 7932 41 10.1128/JVI.76.16.7932-7941.2002 12133997 PMC155131

43 Galluzzi L Brenner C Morselli E Touat Z Kroemer G Viral control of mitochondrial apoptosis PLoS Pathog 2008 4 e1000018 10.1371/journal.ppat.1000018 18516228 PMC2376094

44 Olijslagers S Dege AY Dinsart C Voorhoeve M Rommelaere J Noteborn MH Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin Cancer Gene Ther 2001 8 958 65 10.1038/sj.cgt.7700392 11781658

45 Pietersen AM van der Eb MM Rademaker HJ van den Wollenberg DJ Rabelink MJ Kuppen PJ Specific tumor-cell killing with adenovirus vectors containing the apoptin gene Gene Ther 1999 6 882 92 10.1038/sj.gt.3300876 10505114

46 Branton PE Roopchand DE The role of adenovirus E4orf4 protein in viral replication and cell killing Oncogene 2001 20 7855 65 10.1038/sj.onc.1204862 11753668

47 Chinnery F King CA Elliott T Bateman AR James E Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk Oncoimmunology 2012 1 874 83 10.4161/onci.20636 23162755 PMC3489743

48 Woller N Kühnel F Kubicka S Virus infections in tumors pave the way for tumor-directed DC-vaccines Oncoimmunology 2012 1 208 10 10.4161/onci.1.2.18099 22720244 PMC3377008

49 Diaconu I Cerullo V Hirvinen ML Escutenaire S Ugolini M Pesonen SK Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus Cancer Res 2012 72 2327 38 10.1158/0008-5472.CAN-11-2975 22396493

50 Pesonen S Diaconu I Kangasniemi L Ranki T Kanerva A Pesonen SK Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients Cancer Res 2012 72 1621 31 10.1158/0008-5472.CAN-11-3001 22323527

51 Gomes EM Rodrigues MS Phadke AP Butcher LD Starling C Chen S Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells Clin Cancer Res 2009 15 1317 25 10.1158/1078-0432.CCR-08-1360 19228733

52 Choi KJ Kim JH Lee YS Kim J Suh BS Kim H Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect Gene Ther 2006 13 1010 20 10.1038/sj.gt.3302759 16525479

53 Zamarin D Vigil A Kelly K García-Sastre A Fong Y Genetically engineered Newcastle disease virus for malignant melanoma therapy Gene Ther 2009 16 796 804 10.1038/gt.2009.14 19242529 PMC2882235

54 Wong RJ Chan MK Yu Z Ghossein RA Ngai I Adusumilli PS Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12 Clin Cancer Res 2004 10 4509 16 10.1158/1078-0432.CCR-04-0081 15240543

55 Zhang SN Choi IK Huang JH Yoo JY Choi KJ Yun CO Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF Mol Ther 2011 19 1558 68 10.1038/mt.2011.29 21468000 PMC3149171

56 Parker JN Gillespie GY Love CE Randall S Whitley RJ Markert JM Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors Proc Natl Acad Sci U S A 2000 97 2208 13 10.1073/pnas.040557897 10681459 PMC15779

57 Stephenson KB Barra NG Davies E Ashkar AA Lichty BD Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity Cancer Gene Ther 2012 19 238 46 10.1038/cgt.2011.81 22158521

58 Liu J Wennier S Reinhard M Roy E MacNeill A McFadden G Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits J Virol 2009 83 5933 8 10.1128/JVI.00204-09 19279088 PMC2681933

59 van Rikxoort M Michaelis M Wolschek M Muster T Egorov A Seipelt J Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame PLoS One 2012 7 e36506 10.1371/journal.pone.0036506 22563505 PMC3341362

60 Pesonen S Diaconu I Cerullo V Escutenaire S Raki M Kangasniemi L Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors Int J Cancer 2012 130 1937 47 10.1002/ijc.26216 21630267

61 Burke JM Lamm DL Meng MV Nemunaitis JJ Stephenson JJ Arseneau JC A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer J Urol 2012 188 2391 7 10.1016/j.juro.2012.07.097 23088985

62 Heo J Reid T Ruo L Breitbach CJ Rose S Bloomston M Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Nat Med 2013 19 329 36 10.1038/nm.3089 23396206 PMC4268543

63 Colombo F Barzon L Franchin E Pacenti M Pinna V Danieli D Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results Cancer Gene Ther 2005 12 835 48 10.1038/sj.cgt.7700851 15891772

64 Lun X Alain T Zemp FJ Zhou H Rahman MM Hamilton MG Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin Cancer Res 2010 70 598 608 10.1158/0008-5472.CAN-09-1510 20068158

65 Ram Z Culver KW Oshiro EM Viola JJ DeVroom HL Otto E Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells Nat Med 1997 3 1354 61 10.1038/nm1297-1354 9396605

66 Smyth JW Fleeton MN Sheahan BJ Atkins GJ Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector Gene Ther 2005 12 147 59 10.1038/sj.gt.3302390 15372069

67 Vähä-Koskela MJ Kallio JP Jansson LC Heikkilä JE Zakhartchenko VA Kallajoki MA Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice Cancer Res 2006 66 7185 94 10.1158/0008-5472.CAN-05-2214 16849565

68 Cordaro TA de Visser KE Tirion FH Graus YM Haanen JB Kioussis D Tumor size at the time of adoptive transfer determines whether tumor rejection occurs Eur J Immunol 2000 30 1297 307 10.1002/(SICI)1521-4141(200005)30:5<1297::AID-IMMU1297>3.0.CO;2-C 10820375

69 Li ZY Ni S Yang X Kiviat N Lieber A Xenograft models for liver metastasis: Relationship between tumor morphology and adenovirus vector transduction Mol Ther 2004 9 650 7 10.1016/j.ymthe.2004.01.021 15120325

70 Shayakhmetov DM Li ZY Ni S Lieber A Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases Cancer Res 2002 62 1063 8 11861383

71 Stohrer M Boucher Y Stangassinger M Jain RK Oncotic pressure in solid tumors is elevated Cancer Res 2000 60 4251 5 10945638

72 Bilbao R Bustos M Alzuguren P Pajares MJ Drozdzik M Qian C A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds Gene Ther 2000 7 1824 32 10.1038/sj.gt.3301312 11110414

73 Cairns R Papandreou I Denko N Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment Mol Cancer Res 2006 4 61 70 10.1158/1541-7786.MCR-06-0002 16513837

74 Galluzzi L Vitale I Abrams JM Alnemri ES Baehrecke EH Blagosklonny MV Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012 Cell Death Differ 2012 19 107 20 10.1038/cdd.2011.96 21760595 PMC3252826

75 Grote D Russell SJ Cornu TI Cattaneo R Vile R Poland GA Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice Blood 2001 97 3746 54 10.1182/blood.V97.12.3746 11389012

76 Peng KW TenEyck CJ Galanis E Kalli KR Hartmann LC Russell SJ Intraperitoneal therapy of ovarian cancer using an engineered measles virus Cancer Res 2002 62 4656 62 12183422

77 Kanerva A Zinn KR Peng KW Ranki T Kangasniemi L Chaudhuri TR Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus Gene Ther 2005 12 87 94 10.1038/sj.gt.3302387 15385953

78 Alain T Kim M Johnston RN Urbanski S Kossakowska AE Forsyth PA The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro Br J Cancer 2006 95 1020 7 10.1038/sj.bjc.6603363 17047650 PMC2360720

79 Kim YT Ganly I Brown R Stuart D Acquired resistance to cytolysis of the E1B-attenuated adenovirus, dl1520, in ovarian tumour cell lines Cancer Gene Ther 2003 10 589 90 10.1038/sj.cgt.7700607 12872140

80 Vitale I Galluzzi L Castedo M Kroemer G Mitotic catastrophe: a mechanism for avoiding genomic instability Nat Rev Mol Cell Biol 2011 12 385 92 10.1038/nrm3115 21527953

81 Vitale I Galluzzi L Senovilla L Criollo A Jemaà M Castedo M Illicit survival of cancer cells during polyploidization and depolyploidization Cell Death Differ 2011 18 1403 13 10.1038/cdd.2010.145 21072053 PMC3178421

82 López-Guerrero JA Rayet B Tuynder M Rommelaere J Dinsart C Constitutive activation of U937 promonocytic cell clones selected for their resistance to parvovirus H-1 infection Blood 1997 89 1642 53 9057647

83 Rayet B Lopez-Guerrero JA Rommelaere J Dinsart C Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway J Virol 1998 72 8893 903 9765434 10.1128/jvi.72.11.8893-8903.1998 PMC110306

84 Telerman A Tuynder M Dupressoir T Robaye B Sigaux F Shaulian E A model for tumor suppression using H-1 parvovirus Proc Natl Acad Sci U S A 1993 90 8702 6 10.1073/pnas.90.18.8702 8378352 PMC47426

85 Fisher KD Stallwood Y Green NK Ulbrich K Mautner V Seymour LW Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies Gene Ther 2001 8 341 8 10.1038/sj.gt.3301389 11313809

86 Massari I Donnini A Argentati K Straino S Mangoni A Gaetano C Age-dependent effects of repeated immunization with a first generation adenovirus vector on the immune response and transgene expression in young and old rats Exp Gerontol 2002 37 823 31 10.1016/S0531-5565(02)00011-6 12175482

87 Ikeda K Wakimoto H Ichikawa T Jhung S Hochberg FH Louis DN Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant J Virol 2000 74 4765 75 10.1128/JVI.74.10.4765-4775.2000 10775615 PMC111999

88 Pensiero MN Wysocki CA Nader K Kikuchi GE Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum Hum Gene Ther 1996 7 1095 101 10.1089/hum.1996.7.9-1095 8773511

89 Bernt KM Ni S Gaggar A Li ZY Shayakhmetov DM Lieber A The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors Mol Ther 2003 8 746 55 10.1016/j.ymthe.2003.07.006 14599807

90 Underhill DM Ozinsky A Phagocytosis of microbes: complexity in action Annu Rev Immunol 2002 20 825 52 10.1146/annurev.immunol.20.103001.114744 11861619

91 Doronin K Shashkova EV May SM Hofherr SE Barry MA Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus Hum Gene Ther 2009 20 975 88 10.1089/hum.2009.028 19469693 PMC2829283

92 Ferguson MS Lemoine NR Wang Y Systemic delivery of oncolytic viruses: hopes and hurdles Adv Virol 2012 2012 805629 10.1155/2012/805629 22400027 PMC3287020

93 Brenner C Galluzzi L Kepp O Kroemer G Decoding cell death signals in liver inflammation J Hepatol 2013 In press 10.1016/j.jhep.2013.03.033 23567086

94 Chisholm J Howe K Taj M Zambon M Influenza immunisation in children with solid tumours Eur J Cancer 2005 41 2280 7 10.1016/j.ejca.2005.07.006 16143516

95 Cooksley CD Avritscher EB Bekele BN Rolston KV Geraci JM Elting LS Epidemiology and outcomes of serious influenza-related infections in the cancer population Cancer 2005 104 618 28 10.1002/cncr.21203 15973737

96 Hicks KL Chemaly RF Kontoyiannis DP Common community respiratory viruses in patients with cancer: more than just “common colds” Cancer 2003 97 2576 87 10.1002/cncr.11353 12733157

97 Nemunaitis J Khuri F Ganly I Arseneau J Posner M Vokes E Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer J Clin Oncol 2001 19 289 98 11208818 10.1200/JCO.2001.19.2.289

98 Geevarghese SK Geller DA de Haan HA Hörer M Knoll AE Mescheder A Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver Hum Gene Ther 2010 21 1119 28 10.1089/hum.2010.020 20486770 PMC3733135

99 Hacein-Bey-Abina S von Kalle C Schmidt M Le Deist F Wulffraat N McIntyre E A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency N Engl J Med 2003 348 255 6 10.1056/NEJM200301163480314 12529469

100 Hacein-Bey-Abina S Von Kalle C Schmidt M McCormack MP Wulffraat N Leboulch P LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 Science 2003 302 415 9 10.1126/science.1088547 14564000

101 Eto Y Yoshioka Y Mukai Y Okada N Nakagawa S Development of PEGylated adenovirus vector with targeting ligand Int J Pharm 2008 354 3 8 10.1016/j.ijpharm.2007.08.025 17904316

102 Duncan R Polymer conjugates as anticancer nanomedicines Nat Rev Cancer 2006 6 688 701 10.1038/nrc1958 16900224

103 Morrison J Briggs SS Green N Fisher K Subr V Ulbrich K Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor Mol Ther 2008 16 244 51 10.1038/sj.mt.6300363 18071336

104 Fang J Nakamura H Maeda H The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv Drug Deliv Rev 2011 63 136 51 10.1016/j.addr.2010.04.009 20441782

105 Jain RK Stylianopoulos T Delivering nanomedicine to solid tumors Nat Rev Clin Oncol 2010 7 653 64 10.1038/nrclinonc.2010.139 20838415 PMC3065247

106 Diop-Frimpong B Chauhan VP Krane S Boucher Y Jain RK Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors Proc Natl Acad Sci U S A 2011 108 2909 14 10.1073/pnas.1018892108 21282607 PMC3041115

107 Ganesh S Gonzalez-Edick M Gibbons D Van Roey M Jooss K Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models Clin Cancer Res 2008 14 3933 41 10.1158/1078-0432.CCR-07-4732 18559615

108 Guedan S Rojas JJ Gros A Mercade E Cascallo M Alemany R Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth Mol Ther 2010 18 1275 83 10.1038/mt.2010.79 20442708 PMC2911260

109 Galluzzi L Senovilla L Zitvogel L Kroemer G The secret ally: immunostimulation by anticancer drugs Nat Rev Drug Discov 2012 11 215 33 10.1038/nrd3626 22301798

110 Kaluza KM Vile R Improving the outcome of adoptive cell transfer by targeting tumor escape Oncoimmunology 2013 2 e22059 10.4161/onci.22059 23483796 PMC3583906

111 Pere H Tanchot C Bayry J Terme M Taieb J Badoual C Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer Oncoimmunology 2012 1 326 33 10.4161/onci.18852 22737608 PMC3382865

112 Chiocca EA The host response to cancer virotherapy Curr Opin Mol Ther 2008 10 38 45 18228180

113 Wilson JM Gendicine: the first commercial gene therapy product Hum Gene Ther 2005 16 1014 5 10.1089/hum.2005.16.1014 16149899

114 Peng Z Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers Hum Gene Ther 2005 16 1016 27 10.1089/hum.2005.16.1016 16149900

115 Galluzzi L Vacchelli E Fridman WH Galon J Sautès-Fridman C Tartour E Trial Watch: Monoclonal antibodies in cancer therapy Oncoimmunology 2012 1 28 37 10.4161/onci.1.1.17938 22720209 PMC3376976

116 Vacchelli E Galluzzi L Fridman WH Galon J Sautès-Fridman C Tartour E Trial watch: Chemotherapy with immunogenic cell death inducers Oncoimmunology 2012 1 179 88 10.4161/onci.1.2.19026 22720239 PMC3376992

117 Galluzzi L Vacchelli E Eggermont A Fridman WH Galon J Sautès-Fridman C Trial Watch: Adoptive cell transfer immunotherapy Oncoimmunology 2012 1 306 15 10.4161/onci.19549 22737606 PMC3382856

118 Vacchelli E Galluzzi L Eggermont A Galon J Tartour E Zitvogel L Trial Watch: Immunostimulatory cytokines Oncoimmunology 2012 1 493 506 10.4161/onci.20459 22754768 PMC3382908

119 Galluzzi L Vacchelli E Eggermont A Fridman WH Galon J Sautès-Fridman C Trial Watch: Experimental Toll-like receptor agonists for cancer therapy Oncoimmunology 2012 1 699 716 10.4161/onci.20696 22934262 PMC3429574

120 Vacchelli E Galluzzi L Eggermont A Fridman WH Galon J Sautès-Fridman C Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy Oncoimmunology 2012 1 894 907 10.4161/onci.20931 23162757 PMC3489745

121 Galluzzi L Senovilla L Vacchelli E Eggermont A Fridman WH Galon J Trial watch: Dendritic cell-based interventions for cancer therapy Oncoimmunology 2012 1 1111 34 10.4161/onci.21494 23170259 PMC3494625

122 Senovilla L Vacchelli E Galon J Adjemian S Eggermont A Fridman WH Trial watch: Prognostic and predictive value of the immune infiltrate in cancer Oncoimmunology 2012 1 1323 43 10.4161/onci.22009 23243596 PMC3518505

123 Vacchelli E Martins I Eggermont A Fridman WH Galon J Sautès-Fridman C Trial watch: Peptide vaccines in cancer therapy Oncoimmunology 2012 1 1557 76 10.4161/onci.22428 23264902 PMC3525611

124 Vacchelli E Eggermont A Galon J Sautès-Fridman C Zitvogel L Kroemer G Trial watch: Monoclonal antibodies in cancer therapy Oncoimmunology 2013 2 e22789 10.4161/onci.22789 23482847 PMC3583934

125 Menger L Vacchelli E Kepp O Eggermont A Tartour E Zitvogel L Trial watch: Cardiac glycosides and cancer therapy Oncoimmunology 2013 2 e23082 10.4161/onci.23082 23525565 PMC3601180

126 Vacchelli E Galluzzi L Fridman WH Galon J Sautés-Fridman C Tartour E Trial Watch: Chemotherapy with immunogenic cell death inducers OncoImmunology 2012 1 179 88 10.4161/onci.1.2.19026 22720239 PMC3376992

127 Senovilla L Vacchelli E Garcia P Eggermont A Fridman WH Galon J Trial Watch: DNA vaccines for cancer therapy OncoImmunology 2013 2 e23803 10.4161/onci.23803 23734328 PMC3654598

128 Galluzzi L Vacchelli E Eggermont A Fridman WH Galon J Sautès-Fridman C Trial Watch: Adoptive cell transfer immunotherapy Oncoimmunology 2012 1 306 15 10.4161/onci.19549 22737606 PMC3382856

129 Sinkovics JG Viral oncolysates as human tumor vaccines Int Rev Immunol 1991 7 259 87 10.3109/08830189109114875 1663989

130 Sinkovics JG Horvath JC Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts Int J Oncol 2006 29 765 77 16964374

131 Asada T Treatment of human cancer with mumps virus Cancer 1974 34 1907 28 10.1002/1097-0142(197412)34:6<1907::AID-CNCR2820340609>3.0.CO;2-4 4611607

132 Martuza RL Malick A Markert JM Ruffner KL Coen DM Experimental therapy of human glioma by means of a genetically engineered virus mutant Science 1991 252 854 6 10.1126/science.1851332 1851332

133 Bradbury J Oncolytic viral anti-cancer therapy: a magic bullet? Lancet 2001 357 614 10.1016/S0140-6736(05)71407-0 11558496

134 Chiocca EA Oncolytic viruses Nat Rev Cancer 2002 2 938 50 10.1038/nrc948 12459732

135 Bourke MG Salwa S Harrington KJ Kucharczyk MJ Forde PF de Kruijf M The emerging role of viruses in the treatment of solid tumours Cancer Treat Rev 2011 37 618 32 10.1016/j.ctrv.2010.12.003 21232872

136 Donnelly OG Errington-Mais F Prestwich R Harrington K Pandha H Vile R Recent clinical experience with oncolytic viruses Curr Pharm Biotechnol 2012 13 1834 41 10.2174/138920112800958904 21740364

137 Cerullo V Vähä-Koskela M Hemminki A Oncolytic adenoviruses: A potent form of tumor immunovirotherapy Oncoimmunology 2012 1 979 81 10.4161/onci.20172 23162778 PMC3489766

138 Kaur B Chiocca EA Cripe TP Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress Curr Pharm Biotechnol 2012 13 1842 51 10.2174/138920112800958814 21740359 PMC4233127

139 Li H Zhang X Oncolytic HSV as a vector in cancer immunotherapy Methods Mol Biol 2010 651 279 90 10.1007/978-1-60761-786-0_16 20686972

140 Chiocca EA Abbed KM Tatter S Louis DN Hochberg FH Barker F A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting Mol Ther 2004 10 958 66 10.1016/j.ymthe.2004.07.021 15509513

141 Galanis E Okuno SH Nascimento AG Lewis BD Lee RA Oliveira AM Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas Gene Ther 2005 12 437 45 10.1038/sj.gt.3302436 15647767

142 Ganly I Kirn D Eckhardt G Rodriguez GI Soutar DS Otto R A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 2000 6 798 806 10741699

143 Khuri FR Nemunaitis J Ganly I Arseneau J Tannock IF Romel L a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nat Med 2000 6 879 85 10.1038/78638 10932224

144 Xia ZJ Chang JH Zhang L Jiang WQ Guan ZZ Liu JW [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus] Ai Zheng 2004 23 1666 70 15601557

145 Xu RH Yuan ZY Guan ZZ Cao Y Wang HQ Hu XH [Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer] Ai Zheng 2003 22 1307 10 14693057

146 Hecht JR Bedford R Abbruzzese JL Lahoti S Reid TR Soetikno RM A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma Clin Cancer Res 2003 9 555 61 12576418

147 Reid T Galanis E Abbruzzese J Sze D Wein LM Andrews J Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints Cancer Res 2002 62 6070 9 12414631

148 Hamid O Varterasian ML Wadler S Hecht JR Benson A 3rd Galanis E Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer J Clin Oncol 2003 21 1498 504 10.1200/JCO.2003.09.114 12697873

149 Reid TR Freeman S Post L McCormick F Sze DY Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin Cancer Gene Ther 2005 12 673 81 10.1038/sj.cgt.7700819 15803147

150 DeWeese TL van der Poel H Li S Mikhak B Drew R Goemann M A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy Cancer Res 2001 61 7464 72 11606381

151 Freytag SO Khil M Stricker H Peabody J Menon M DePeralta-Venturina M Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer Cancer Res 2002 62 4968 76 12208748

152 Freytag SO Stricker H Pegg J Paielli D Pradhan DG Peabody J Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer Cancer Res 2003 63 7497 506 14612551

153 Kimball KJ Preuss MA Barnes MN Wang M Siegal GP Wan W A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases Clin Cancer Res 2010 16 5277 87 10.1158/1078-0432.CCR-10-0791 20978148 PMC2970766

154 Vasey PA Shulman LN Campos S Davis J Gore M Johnston S Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer J Clin Oncol 2002 20 1562 9 10.1200/JCO.20.6.1562 11896105

155 Nemunaitis J Senzer N Sarmiento S Zhang YA Arzaga R Sands B A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients Cancer Gene Ther 2007 14 885 93 10.1038/sj.cgt.7701080 17704755

156 Nemunaitis J Tong AW Nemunaitis M Senzer N Phadke AP Bedell C A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors Mol Ther 2010 18 429 34 10.1038/mt.2009.262 19935775 PMC2839300

157 Markovitz NS Baunoch D Roizman B The range and distribution of murine central nervous system cells infected with the gamma(1)34.5- mutant of herpes simplex virus 1 J Virol 1997 71 5560 9 9188630 10.1128/jvi.71.7.5560-5569.1997 PMC191798

158 Harrow S Papanastassiou V Harland J Mabbs R Petty R Fraser M HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival Gene Ther 2004 11 1648 58 10.1038/sj.gt.3302289 15334111

159 Markert JM Liechty PG Wang W Gaston S Braz E Karrasch M Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM Mol Ther 2009 17 199 207 10.1038/mt.2008.228 18957964 PMC2834981

160 Markert JM Medlock MD Rabkin SD Gillespie GY Todo T Hunter WD Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial Gene Ther 2000 7 867 74 10.1038/sj.gt.3301205 10845725

161 Papanastassiou V Rampling R Fraser M Petty R Hadley D Nicoll J The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study Gene Ther 2002 9 398 406 10.1038/sj.gt.3301664 11960316

162 Todo T Martuza RL Rabkin SD Johnson PA Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing Proc Natl Acad Sci U S A 2001 98 6396 401 10.1073/pnas.101136398 11353831 PMC33479

163 Kimata H Imai T Kikumori T Teshigahara O Nagasaka T Goshima F Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer Ann Surg Oncol 2006 13 1078 84 10.1245/ASO.2006.08.035 16865590

164 Mace AT Ganly I Soutar DS Brown SM Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma Head Neck 2008 30 1045 51 10.1002/hed.20840 18615711

165 Fujimoto Y Mizuno T Sugiura S Goshima F Kohno S Nakashima T Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma Acta Otolaryngol 2006 126 1115 7 10.1080/00016480600702100 16923721

166 Harrington KJ Hingorani M Tanay MA Hickey J Bhide SA Clarke PM Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck Clin Cancer Res 2010 16 4005 15 10.1158/1078-0432.CCR-10-0196 20670951

167 White RR Stanley WE Johnson JL Tyler DS Seigler HF Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis Ann Surg 2002 235 879 87 10.1097/00000658-200206000-00017 12035046 PMC1422519

168 Kaufman HL Kim DW DeRaffele G Mitcham J Coffin RS Kim-Schulze S Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma Ann Surg Oncol 2010 17 718 30 10.1245/s10434-009-0809-6 19915919

169 MacKie RM Stewart B Brown SM Intralesional injection of herpes simplex virus 1716 in metastatic melanoma Lancet 2001 357 525 6 10.1016/S0140-6736(00)04048-4 11229673

170 Senzer NN Kaufman HL Amatruda T Nemunaitis M Reid T Daniels G Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma J Clin Oncol 2009 27 5763 71 10.1200/JCO.2009.24.3675 19884534

171 Nakao A Kasuya H Sahin TT Nomura N Kanzaki A Misawa M A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer Cancer Gene Ther 2011 18 167 75 10.1038/cgt.2010.65 21102422

172 Fong Y Kim T Bhargava A Schwartz L Brown K Brody L A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer Mol Ther 2009 17 389 94 10.1038/mt.2008.240 19018254 PMC2835058

173 Hu JC Coffin RS Davis CJ Graham NJ Groves N Guest PJ A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor Clin Cancer Res 2006 12 6737 47 10.1158/1078-0432.CCR-06-0759 17121894

174 Freeman AI Zakay-Rones Z Gomori JM Linetsky E Rasooly L Greenbaum E Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme Mol Ther 2006 13 221 8 10.1016/j.ymthe.2005.08.016 16257582

175 Laurie SA Bell JC Atkins HL Roach J Bamat MK O’Neil JD A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization Clin Cancer Res 2006 12 2555 62 10.1158/1078-0432.CCR-05-2038 16638865

176 Pecora AL Rizvi N Cohen GI Meropol NJ Sterman D Marshall JL Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers J Clin Oncol 2002 20 2251 66 10.1200/JCO.2002.08.042 11980996

177 Geletneky K Huesing J Rommelaere J Schlehofer JR Leuchs B Dahm M Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol BMC Cancer 2012 12 99 10.1186/1471-2407-12-99 22436661 PMC3425127

178 Vidal L Pandha HS Yap TA White CL Twigger K Vile RG A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer Clin Cancer Res 2008 14 7127 37 10.1158/1078-0432.CCR-08-0524 18981012

179 Karapanagiotou EM Roulstone V Twigger K Ball M Tanay M Nutting C Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies Clin Cancer Res 2012 18 2080 9 10.1158/1078-0432.CCR-11-2181 22316603 PMC5553618

180 Galanis E Markovic SN Suman VJ Nuovo GJ Vile RG Kottke TJ Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma Mol Ther 2012 20 1998 2003 10.1038/mt.2012.146 22871663 PMC3464629

181 Morris DG Feng X Difrancesco LM Fonseca K Forsyth PA Paterson AH REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors Invest New Drugs 2012 In press 10.1007/s10637-012-9865-z 22886613

182 Hwang TH Moon A Burke J Ribas A Stephenson J Breitbach CJ A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma Mol Ther 2011 19 1913 22 10.1038/mt.2011.132 21772252 PMC3188739

183 Mastrangelo MJ Maguire HC Jr. Eisenlohr LC Laughlin CE Monken CE McCue PA Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma Cancer Gene Ther 1999 6 409 22 10.1038/sj.cgt.7700066 10505851

184 Park BH Hwang T Liu TC Sze DY Kim JS Kwon HC Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial Lancet Oncol 2008 9 533 42 10.1016/S1470-2045(08)70107-4 18495536

185 Liu BL Robinson M Han ZQ Branston RH English C Reay P ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties Gene Ther 2003 10 292 303 10.1038/sj.gt.3301885 12595888

186 Kelly K Nawrocki S Mita A Coffey M Giles FJ Mita M Reovirus-based therapy for cancer Expert Opin Biol Ther 2009 9 817 30 10.1517/14712590903002039 19527106

187 Zhang Q Liang C Yu YA Chen N Dandekar T Szalay AA The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation Mol Genet Genomics 2009 282 417 35 10.1007/s00438-009-0475-1 19701652 PMC2746888

188 Zitvogel L Kroemer G Targeting PD-1/PD-L1 interactions for cancer immunotherapy Oncoimmunology 2012 1 1223 5 10.4161/onci.21335 23243584 PMC3518493

189 Madan RA Heery CR Gulley JL Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity Oncoimmunology 2012 1 1167 8 10.4161/onci.20591 23170267 PMC3494633

190 Skelding KA Barry RD Shafren DR Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride Invest New Drugs 2012 30 568 81 10.1007/s10637-010-9614-0 21170760

191 Kanerva A Nokisalmi P Diaconu I Koski A Cerullo V Liikanen I Anti-viral and anti-tumor T-cell immunity in patients treated with GMCSF coding oncolytic adenovirus Clin Cancer Res 2013 In press 10.1158/1078-0432.CCR-12-2546 23493351

192 Bauerschmitz GJ Kanerva A Wang M Herrmann I Shaw DR Strong TV Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer Int J Cancer 2004 111 303 9 10.1002/ijc.20217 15197787

193 Fueyo J Alemany R Gomez-Manzano C Fuller GN Khan A Conrad CA Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway J Natl Cancer Inst 2003 95 652 60 10.1093/jnci/95.9.652 12734316

194 Reddy PS Burroughs KD Hales LM Ganesh S Jones BH Idamakanti N Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers J Natl Cancer Inst 2007 99 1623 33 10.1093/jnci/djm198 17971529 PMC5261858

195 Goetz C Dobrikova E Shveygert M Dobrikov M Gromeier M Oncolytic poliovirus against malignant glioma Future Virol 2011 6 1045 58 10.2217/fvl.11.76 21984883 PMC3187927

196 Msaouel P Opyrchal M Domingo Musibay E Galanis E Oncolytic measles virus strains as novel anticancer agents Expert Opin Biol Ther 2013 13 483 502 10.1517/14712598.2013.749851 23289598 PMC3810368

197 Ramesh N Ge Y Ennist DL Zhu M Mina M Ganesh S CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer Clin Cancer Res 2006 12 305 13 10.1158/1078-0432.CCR-05-1059 16397056

198 Mori I Liu B Goshima F Ito H Koide N Yoshida T HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2 Microbes Infect 2005 7 1492 500 10.1016/j.micinf.2005.05.007 16054416

199 Takakuwa H Goshima F Nozawa N Yoshikawa T Kimata H Nakao A Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice Arch Virol 2003 148 813 25 10.1007/s00705-002-0944-x 12664303

200 Yaacov B Eliahoo E Lazar I Ben-Shlomo M Greenbaum I Panet A Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors Cancer Gene Ther 2008 15 795 807 10.1038/cgt.2008.31 18535620

201 Grekova SP Rommelaere J Raykov Z Parvoviruses-tools to fine-tune anticancer immune responses Oncoimmunology 2012 1 1417 9 10.4161/onci.21097 23243613 PMC3518522

202 Duntsch CD Zhou Q Jayakar HR Weimar JD Robertson JH Pfeffer LM Recombinant vesicular stomatitis virus vectors as oncolytic agents in the treatment of high-grade gliomas in an organotypic brain tissue slice-glioma coculture model J Neurosurg 2004 100 1049 59 10.3171/jns.2004.100.6.1049 15200120

203 Obuchi M Fernandez M Barber GN Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity J Virol 2003 77 8843 56 10.1128/JVI.77.16.8843-8856.2003 12885903 PMC167243

204 Egilmez NK Harden JL Rowswell-Turner RB Chemoimmunotherapy as long-term maintenance therapy for cancer Oncoimmunology 2012 1 563 5 10.4161/onci.19369 22754788 PMC3382905

205 Amiset L Fend L Gatard-Scheikl T Rittner K Duong V Rooke R TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy Oncoimmunology 2012 1 1271 80 10.4161/onci.21479 23243590 PMC3518499

206 Holcmann M Drobits B Sibilia M How imiquimod licenses plasmacytoid dendritic cells to kill tumors Oncoimmunology 2012 1 1661 3 10.4161/onci.22033 23264929 PMC3525638

207 Peng W Lizée G Hwu P Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer Oncoimmunology 2013 2 e22691 10.4161/onci.22691 23524510 PMC3601154

208 Rommelfanger DM Grau MC Diaz RM Ilett E Alvarez-Vallina L Thompson JM The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice Mol Ther 2013 21 348 57 10.1038/mt.2012.204 23011032 PMC3594029

209 Kottke T Chester J Ilett E Thompson J Diaz R Coffey M Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy Mol Ther 2011 19 1802 12 10.1038/mt.2011.147 21792179 PMC3188745

210 Kroemer G Galluzzi L Kepp O Zitvogel L Immunogenic cell death in cancer therapy Annu Rev Immunol 2013 31 51 72 10.1146/annurev-immunol-032712-100008 23157435

211 Martins I Kepp O Schlemmer F Adjemian S Tailler M Shen S Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress Oncogene 2011 30 1147 58 10.1038/onc.2010.500 21151176